EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

38476 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 BONE DENSITY DECREASED 13877
1 CHRONIC KIDNEY DISEASE 8346
2 OSTEONECROSIS 7646
3 BONE LOSS 7522
4 RENAL INJURY 7396
5 RENAL FAILURE 7184
6 MULTIPLE FRACTURES 6805
7 SKELETAL INJURY 6594
8 TOOTH LOSS 6543
9 OSTEOPOROSIS 6034
See all common reactions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SKELETAL INJURY 6594 0.6961
1 BONE DEMINERALISATION 283 0.6345
2 BONE LOSS 7522 0.6328
3 BONE DENSITY DECREASED 13877 0.5252
4 TOOTH INJURY 1623 0.5202
5 MULTIPLE FRACTURES 6805 0.5067
6 CLOACAL EXSTROPHY 25 0.4630
7 ACUTE HIV INFECTION 77 0.4118
8 BLADDER AGENESIS 26 0.4000
9 TOOTH LOSS 6543 0.3966
See all enriched reactions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE